Somatostatin receptors in normal and acromegalic somatotroph cells: the U-turn of the clinician to immunohistochemistry report – a review

NINA IONOVICI1), MARA CARSOȚE2,3), DANA CRISTINA TERZEA3,4), ANCA MIHAELA PREDESCU5), ANNE-MARIE RAUTEN6), MIHAELA POPESCU7)

1)Department of Occupational Medicine, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Romania
2)Department of Endocrinology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
3)Department of Endocrinology, C. I. Parhon National Institute of Endocrinology, Bucharest, Romania
4)Department of Pathology, Onco-Team Diagnostic, Royal Hospital, Bucharest, Romania
5)Department of Histology, Faculty of Dental Medicine, University of Medicine and Pharmacy of Craiova, Romania
6)Department of Orthodontics, University of Medicine and Pharmacy of Craiova, Romania
7)Department of Endocrinology, University of Medicine and Pharmacy of Craiova, Romania

Abstract
This is a narrative review of literature introducing somatostatin receptors (SSTRs) as part of understanding the somatotroph cells since they are positive in normal cells but also in tumoral cells as seen in somatotropinoma, a growth hormone (GH)-producing neoplasia, which causes acromegaly. They are five subtypes of SSTRs (1 to 5), which are immunohistochemically positive in different proportions in somatotropinomas. SSTR types 2 and 5 are most frequent in GH-secreting adenomas and they are both targeted by medical therapy with somatostatin analogues (SSTAs) like first generation Octreotide and Lanreotide (mainly targeting SSTR2) and second generation Pasireotide (with highest affinity for SSTR5), thus heterogeneous SSTRs configuration into the tumor explains different pattern of response to treatment and it might predict it once the SSTRs immunostaining is performed. Monoclonal antibodies are used for immunohistochemical detection of SSTRs; currently, a lack of standardization is presented, and scoring systems, such as Volante, H-score or human epidermal growth factor receptor 2 (HER2)-score, are applied. Immunoreactive markers like SSTRs are the U-turn in clinical practice regarding somatotropinomas since the configuration of subtypes 2 and 5 explains the responsiveness to medical therapy like SSTA. Further achievement of disease control is imperiously necessary because acromegaly has an increased rate of morbidity and mortality.

Keywords: somatostatin receptors, somatotropinomas, immunohistochemistry.

Introduction
Somatostatin receptors (SSTRs) are part of understanding the somatotroph cells (since they are positive in normal cells but also in tumoral cells as seen in somatotropinoma, a growth hormone (GH)-producing neoplasia, which causes acromegaly [1, 2]. SSTRs ligands are the physiological hormone somatostatin (SST) and the class of drugs designed to be long-acting somatostatin analogues (SSTAs) like first generation Octreotide and Lanreotide and newly introduced in daily endocrine practice Pasireotide, a second generation SSTA, which are used as treatment in acromegaly [1, 2]. SSTRs are heterogeneously expressed in GH-secreting tumors; SSTAs have different affinities for them, and this becomes a crucial aspect in understanding why some cases of acromegaly have a better response to one generation or another of SSTAs [1, 3–5].

They are five subtypes of SSTRs; they are immunohistochemically positive in different proportions in somatotropinomas [4, 5]. The most important immunostaining is for SSTR types 2 and 5 because they are targeted by SSTAs as main medical therapy in acromegaly [1, 4–6]. SSTR2 expression is lower in pre-treated acromegalic patients with SSTAs and/or GH receptor-blocking medication like Pegvisomant, when compare to drug naïve acromegalic subjects, because therapy induces a down-regulation of SSTRs [3]. Resistance to SSTAs involves signal transduction anomalies of SSTRs [5, 7]. Also, cases with partial response or partial resistance to SSTAs have been described [5]. New biomarkers as immunohistochemistry expression of E-cadherin are under investigation in order to predict the response to SSTAs [7]. Monoclonal antibodies are used for immunohistochemical detection of SSTRs; currently, a lack of standardization is presented and scoring systems, such as Volante, H-score, and human epidermal growth factor receptor 2 (HER2)-score, are used [4, 8].

Aim
We aimed to introduce general data on a modern topic: the use of SSTRs immunostaining in better understanding the normal function of somatotroph cells, as well as their application in acromegaly, especially when choosing the medical therapy with SSTAs.
**Method**

This is a narrative review of literature based on a PubMed research using as keywords “somatostatin receptor”, “acromegaly”, “somatostatin analogue”, “somatostatin”. Most of the papers included are from 2016–2019. The topic is introduced based on a point of view related to immunohistochemistry report, as well as endocrine approach of acromegaly both as diagnosis and therapy. In order to highlight the narrative review, some captures of SSRTs immunohistochemistry, as well as computed tomography (CT) in a case of acromegaly are introduced. All the images are priory unpublished.

**General data**

**Immunostaining and molecular biology aspects of SSTRs**

SSTR is a Gα-protein coupled receptor, which inhibits adenylate cyclase and further decreases cyclic adenosine monophosphate (cAMP) production, thus causing a lowering of calcium into the cell [1, 9]. SSTRs are activated by SST, which represents an inhibitory polypeptide with 14, respective 28 amino acids, depending on active form, both are derived from a large precursor molecule called preproSST [9, 10]. SST, a cyclopeptide, is also known as SST-release inhibitory factor [11]. The normal role of hypothalamus-related SST is to inhibit pituitary hormones secretion like GH, thyroid stimulating hormone (TSH), adrenocorticotropic hormone (ACTH) and prolactin [9, 10].

Some tumors display SSTRs-like neuroendocrine tumors (NETs), rare type of oncocytomas (like spindle cell oncocytoma), thus their immunohistochemical analysis might indicate SSTAs as therapy based on an individual approach, and also it might help understanding tumor progression [12–14]. For instance, down-regulation of SSTR2 subtype in small intestinal NETs is correlated with neoplasia progression at the level of intestinal wall [13]. Further applications of SSTRs are represented by peptide receptor radionuclide therapy (PRRT) as applied in NETs including pheochromocytomas and paragangliomas [14–16]. Also, the assessment of SSTRs configuration is a clue of metastasis identification from a primary tumor, which may display the same configuration as primary lesion or a dedifferentiation process [14, 16–18]. Moreover, immuno-blotting assesses and reverse transcription polymerase chain reaction (RT–PCR) for SSTRs recently revealed a different pattern for subtypes 1 and 5 in follicular and anaplastic carcinoma of the thyroid [19]. It seems that increased expression of SSTR2 and SSTR5 is correlated with a poor prognosis in medullary thyroid carcinoma [20].

The large scale of SSTRs-positive tumors makes very useful their immunostaining [21]. Manual assessment of SSTRs is rather complicated and automated evaluation simplified the procedure [21, 22]. Immunohistochemistry report on paraffin sections uses specific monoclonal antibodies against SSTR of either rabbit, rat, and mouse origin [21, 22].

**Immunohistochemistry of SSTRs in pituitary somatotroph cells**

SSTRs are positive in all pituitary cells including corticotroph, lactotroph and thyrotroph cells, not only somatotroph cells [9, 10]. Apart from endocrine inhibitory role, SST exerts an influence on cell cycle by inducing apoptosis [9, 10]. The main effects of SSTRs are introduced in Figure 1.

**Figure 1 – SST and SSTAs intervention via SSTRs activation at cellular level, as explained in the text. SST: Somatostatin; SSTAs: Somatostatin analogues; SSTRs: Somatostatin receptors.**

Somatotropinoma mainly expresses SSTR2, which are targeted by first-line generation SSTAs Octreotide and Lanreotide [9, 11]. But the heterogeneity of the SSTRs in the tumor allows only a partial control of acromegaly in 50–70% of cases [9, 11, 23]. The second line SSTAs Pasireotide (SOM230) was recently introduced in medical practice and it has a much higher affinity for SSTR5, thus some tumors are better controlled by second line medical therapy [11, 24]. The SSTAs affinity for SSTRs, as well as their expression in somatotroph cells, are introduced in Figure 2.

**Figure 2 – The expression of SSTRs in normal and tumoral somatotroph cells. SSTAs bind SSTRs with different affinities – the higher binding capacity of each SST generation is represented by red arrows. SSTAs: Somatostatin analogues; SSTRs: Somatostatin receptors.**

Most current acromegaly protocols of daily endocrine practice include the therapy with long acting Pasireotide only in cases proved as resistant to first line medical treatment like Octreotide or Lanreotide [11, 24, 25]. The activation of SSTRs pathways in somatotroph cells is followed by inhibition of GH secretion (the main effect) and (secondary) GH production and cell proliferation [1, 11]. Most hormonal effects in acromegaly are mediated by SSTR2 and SSTR5, thus their immunostaining in a
somatotropinoma may be important, while medical therapy also targets SSTR2 and SSTR5 [11, 26]. The relationship between SSTRs and SSTAs of first and second generation is introduced in Figure 3. In somatotroph cells of somatotropinoma, an interaction between aryl hydrocarbon receptor-interacting protein (AIP) gene downstream including AIP immunostaining and SSTRs expression might reflect the response to SSTAs [27].

Pituitary corticotroph cells also express SSTRs including in abnormal conditions, for instance, in corticotropinomas (ACTH-producing adenomas or corticotropinomas which cause Cushing’s disease) [9, 24]. In this case, SSTR5 are most frequently seen because SSTR2 are down-regulated by chronic cortisol excess [9, 24]. Since Pasireotide is a multireceptor-targeted STA with a high SSTR5 affinity, it has also been used in Cushing’s disease [24–29]. Non-functioning pituitary adenomas also express SSTRs but to a lesser extent [30].

Overall, pituitary tumors without or without secretory profile are usually benign masses with a lent rate of development expressing SSTR, such as: somatotropinomas – type 2 and 5 in different ratios (more frequent type 2); corticotropinomas – type 2 and 5 (typically synchronous expression), thyrotropinomas – type 2 with co-expression for SSTR3 and SSR5, prolactinomas – type 1 and 5, non-functioning adenomas – mostly SSTR3, followed by SSTR2 and then SSTR5 [23, 31]. The SSTRs expression in functioning and non-functioning pituitary adenomas is introduced in Figure 4.

Acromegaly and applications of SSTRs

Acromegaly is caused in 95% of cases by a pituitary GH-producing adenoma (80% of somatotropinomas have more than 1 cm diameter meaning a macroadenoma) [1, 32, 33]. Increased pituitary-released GH and secondary hepatic insulin-like growth factor-I (IGF-1) elevation cause metabolic anomalies, with high rate of morbidity and mortality, and associated cost-effectiveness of therapy [1, 32–34]. These are the main reasons of continuous seeking to achieve disease control through adequate medical and surgical management [35]. Tissular studies showed an overexpression of GH and its receptor plays an oncogenic role, one of the reasons to try control GH excess [36].

Medical therapy is the first line of approach after unsuccessful transsphenoidal hypophysectomy [35, 37, 38]. In Figure 5 (A–C), we introduce a postoperative pituitary imagery aspect in an adult female with acromegaly (a prior unpublished case). Pathological report after neurosurgery usually shows an adenoma with somatotroph cells [38]. We introduce Hematoxylin–Eosin (HE) aspect of somatotroph cells in a case of GH-producing adenoma, in Figure 6. About 10% of cases associate a co-secretion of prolactin [35, 37, 38]. About 20% of all pituitary adenomas are GH-producing neoplasia [39].

Figure 3 – SSTAs intervention on somatotroph cells of GH-producing adenomas depending on SSTRs expression in tumor. GH: Growth hormone; SSTAs: Somatostatin analogues; SSTRs: Somatostatin receptors.

Figure 4 – SSTRs expression in pituitary adenomas with/without specific hormonal production. A heterogeneous expression of SSTRs is seen in tumors with endocrine function like GH, prolactin, TSH, ACTH or in non-functioning adenomas. ACTH: Adrenocorticotropic hormone; GH: Growth hormone; SSTRs: Somatostatin receptors; TSH: Thyroid-stimulating hormone.

Figure 5 – Pituitary CT (multislice 16, spiral technique) of a 68-year-old acromegalic patient to whom selective hypophysectomy of the microsomatotrophinoma was performed. Active post-operative disease makes the patient candidate for medical therapy. Monthly 20 mg Octreotide LAR® was offered to the patient. See below postoperative aspect of the tumor during first year after surgery at different plans. (Prior unpublished case). (A) Detail of sella turcica. A right microadenoma is presented as postoperative remnant. (B) Yellow arrow: transsphenoidal posthypophysectomy aspect. Red arrow: right microsomatotrophinoma after surgery. (C) Frontal plane. Pituitary area after surgery with GH-producing adenoma remnants. CT: Computed tomography; GH: Growth hormone.
Figure 6 – Histological report in a case of GH-producing pituitary adenoma with clinical phenotype of acromegaly (HE staining, ×200). This is the case of young acromegalic male diagnosed with a large pituitary macroadenoma who as first referred for pituitary neurosurgery. The capture is provided after selective transsphenoidal hypophysectomy. GH: Growth hormone; HE: Hematoxylin–Eosin.

Recently, the immunostaining of tumoral somatotroph cells became important because therapy response to SSTAs is modulated by SSTRs expression and it might predict the type of response thus it indicates which SSTA should be used [2, 35, 40, 41] (Figure 7, A and B). As mentioned, the focus in on SSTR2 and SSTR5: if a somatotropinoma has mostly type 2 is more likely that acromegaly will be controlled with first line medical SSTAs molecules, while in tumors with type 5 preponderance, the subjects become candidates to Pasireotide in active disease under first generation SSTAs [42–44]. Pasireotide is a multi-targeted analogue, meaning that it binds mainly SSTR5 but also SSTR1, SSTR2, and SSTR3 [23]. Known the SSTRs configuration at somatotropinoma level, we may predict the response to therapy [45, 46]. There is still controversial issue related to cost-effective approach if SSTRs immunostaining should be routinely performed in each tumor or therapeutic test with both SSTAs generations (Pasireotide is acromegaly is active under Octreotide/Lanreotide) is a better solution [45, 46]. Further standard protocols are expected in order to refine case-treating strategies combining endocrine profile and immunochemistry report.

Figure 7 – Immunohistochemistry report: SSTRs in somatotroph cells of somatotropinoma (histological report was introduced above). (A) SSTR2 positive with moderate expression (of 33–66%) in tumoral cells, IRS of 4 (intermediate score), SSTR2 polyclonal antibody kit, 1:75 dilution (×200). (B) SSTR5 with moderate-to-high expression (>66%) in tumoral cells, IRS of 6 (intermediate score), SSTR5 polyclonal antibody kit, 1:200 dilution (×400). IRS: Immunoreactive score; SSTRs: Somatostatin receptors.

**Discussions**

**Controversies**

SSTRs assays in daily clinical practice represent a major step ahead that improves the medical approach thus the prognosis of acromegaly. This topic is very recent, and some data are still necessary to better place the SSTRs immunostaining in clinical guidelines of acromegaly. Current limits of the topic are related to the fact that acromegaly treatment still represents a challenge in daily practice since routine tests of SSTR immunoreactions are not use. Also, the national protocol of SSTA reimbursement should include SSTR immunohistochemistry in order to choose the adequate line of medical therapy in patients with post-operative active disease. Moreover, another current limit of SSTR immunostaining is represented by the need of homogenous scales of assessment. However, the key message is the fact that understanding the immunochemistry profile is the pivotal approach in choosing the medical therapy for active acromegaly after neurosurgery was unsuccessful. Even the topic is rather a cutting edge in acromegaly approach; in the future, this will become a standard care in acromegalic subjects who were first treated with surgical intervention as the current guidelines indicate. Knowing the immunochemistry profile represents probably also a more cost-efficient approach since first live versus second line medication response depends on SSTR profile. A paper released in 2019 included as predictive marker of postsurgical therapy that SSTR expression is needed to assess the type of response to medical therapy with SSTAs [47]. But the immunohistochemistry of somatotropinoma is a part of the complex panel of predictive factors in addition to hormonal assays and imagery appearance of the tumor [47].
Integrating the immunochemistry profile in daily routine practice

The assessment of SSTRs is part of a larger frame that includes the use of immunochemistry in usual practical approach of tumors that exerts hormonal activity or even those detected as incidentalomas like neuroendocrine neoplasia or ovarian tumors [48–50]. NETs represent a large area of diseases located at any organ where a variety of SSTRs combinations are registered [48–51]. The present of the hormonal receptors at the surface of the tumor allows a new route of therapy including radiolabeled peptides [51]. Regarding the subtypes of SSTRs, the type 2 plays the major role because it is positive in most gastrointestinal neuroendocrine neoplasia [51]. It seems that overexpression of type 2 SSTRs goes through their up-regulation probably due to epigenetic factors [51]. Currently, SST-like molecules (or analogues) are used for tumors with active neuroendocrine profile but for the future antagonists of SST might find a place in the treatment regimen of mentioned tumors [51]. In rare cases of NETs that lack the expression of SSTR type 2, the role of SSTAs as part of therapeutic management is limited [51]. In addition to SSTRs configuration, other neuroendocrine markers are useful for immunostaining assays of NETs like chromogranin A (in association with blood assessment) or synaptophysin, etc. [52]. The blood neuroendocrine markers profile also includes serotonin or neuron-specific enolase, while for 24-hour urine the 5-hydroxyindole-acetic acid evaluation is useful [52, 53]. SSTRs domain is actually more complex [54]. Currently, their labelling with tracers like ⁶⁸Gallium (⁶⁸Ga) represents an elegant approach for advances imaging techniques like ⁶⁸Ga–SSTR positron emission tomography (⁶⁸Ga–SSTR–PET) [54]. The use of ⁶⁸Ga–SSTR–PET may become an independent prognostic tool as pointed by a meta-analysis published in 2019 by Lee & Kim [54]. The above-mentioned article includes eight studies comprising almost 500 patients with NETs of different grades regarding the differentiation profile [54]. The results of ⁶⁸Ga–SSTR–PET analysis as predictor factor seem even more important than the tumor site or the type of tracer [54]. PET imaging based on SSTRs overexpression at the level of NETs (traditionally at gastro-entero-pancreatic site) is mostly targeted to SSTR2 [55]. ⁶⁸Ga-Dotatate–PET offers the advantages of a relatively low radiation dose in association to the possibility of results quantification and it seems superior to ¹¹¹Inium (¹¹¹In)-Pentetrotide according to some studies [55]. However, the use of SSTR imaging techniques is not adequate for a pituitary somatotropinoma in daily practice.

Conclusions

Immunoreactive markers like SSTRs are the U-turn in clinical practice regarding somatotropinomas since the configuration of subtypes 2 and 5 explains the responsiveness to medical therapy like SSTA. Further achievement of disease control is imperatively necessary since the condition has an increased rate of morbidity and mortality.

Conflict of interests

The authors declare that they have no conflict of interests.

Acknowledgments

The immunohistochemistry capture of the SSTRs was based on Thermo Fisher polyclonal SSTR2 and SSTR5 antibody kit provided by unrestricted Novartis grant. None of the figures has been priory published.

References

[1] Ben-Shlomo A, Liu NA, Melmed S. Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas. Pituitary, 2017, 20(1):93–99. https://doi.org/10.1007/s11102-016-0778-2 PMID: 27900635
[2] Dineen R, Stewart PM, Sherlock M. Acromegaly. QJM, 2017, 110(7):411–420. https://doi.org/10.1093/qjmed/hcw004 PMID: 28873451
[3] Franck SE, Gatto F, van der Lely AJ, Janssen JAMJ, Dallegna AHG, Nagtegaal AP, Höffland LJ, Negers SJCM. Somatostatin receptor expression in GH-secreting pituitary adenomas treated with long-acting somatostatin analogues in combination with pegvisomant. Neuroendocrinology, 2017, 105(1):44–53. https://doi.org/10.1159/000448429 PMID: 27455094 PMCID: PMC4575231
[4] Kasajima A, Papotti M, Ito W, Brizzi MP, La Salvia A, Rapa I, Tachibana T, Yazdani S, Sasanò H, Volante M. High interlaboratory and interobserver agreement of somatostatin receptor immunohistochemical determination and correlation with response to somatostatin analogs. Hum Pathol, 2018, 72:144–152. https://doi.org/10.1016/j.humpath.2017.11.008 PMID: 29180250
[5] Paragioiola RM, Corsello SM, Salvatori R. Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance. Pituitary, 2017, 20(1):109–115. https://doi.org/10.1007/s11102-016-0768-4 PMID: 27778296
[6] Rafferty J, Nagaraj H, McCloskey AP, Huwaitat R, Porter S, Albadr A, Laverty G. Peptide therapeutics and the pharmaceutical industry: barriers encountered translating from the laboratory to patients. Curr Med Chem, 2016, 23(37):4231–4259. https://doi.org/10.2174/09298733236661609195222 PMID: 27633684
[7] Venegas-Moreno E, Flores-Martínez A, Dios E, Vazquez-Borrego MC, Ibañez-Costa A, Madrazo-Altuba A, Japón MA, Castaño JP, Luque RM, Cano DA, Soto-Moreno A. E-cadherin expression is associated with somatostatin analogue response in acromegaly. J Cell Mol Med, 2019, 23(5):3088–3096. https://doi.org/10.1111/jcmm.13851 PMID: 30843342 PMCID: PMC6484433
[8] Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Kasajima A, Papotti M, Ito W, Brizzi MP, La Salvia A, Rapa I, Castaño JP, Luque RM, Cano DA, Soto-Moreno A. E-cadherin expression is associated with somatostatin analogue response in acromegaly. J Cell Mol Med, 2019, 23(5):3088–3096. https://doi.org/10.1111/jcmm.13851 PMID: 30843342 PMCID: PMC6484433
[9] Kasajima A, Papotti M, Ito W, Brizzi MP, La Salvia A, Rapa I, Cano DA, Soto-Moreno A, E-cadherin expression is associated with somatostatin analogue response in acromegaly. J Cell Mol Med, 2019, 23(5):3088–3096. https://doi.org/10.1111/jcmm.13851 PMID: 30843342 PMCID: PMC6484433
[10] Molina T, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C, De Rosa G, Dogliotti L, Colao A, Papotti M. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol, 2007, 20(11):1172–1182. https://doi.org/10.1038/modpathol.3800954 PMID: 17873898
[11] Cuebas-Ramos D, Flesieru M. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. J Mol Endocrinol, 2014, 52(3):R223–R240. https://doi.org/10.1530/JME-14-0011 PMID: 24647046
[12] Sun L, Coy DH. Somatostatin and its analogs. Curr Drug Targets, 2016, 17(5):529–537. https://doi.org/10.2174/138945016666141205163548 PMID: 26951062
[13] Günther T, Tulipano G, Dournaud P, Boussquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ, Culler M, Melmed S, Schulz S. International Union of Basic and Clinical Pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature. Pharmacol Rev, 2018, 70(4):763–835. https://doi.org/10.1124/pr.117.05388 PMID: 30232095 PMCID: PMC6148080
[14] Soukop J, Kasparova P, Kohout A, Rychly B, Skarkova V, Syrucer M, Gabalec F. Evaluation of expression of somatostatin receptor 1, 2, 3, 5 and dopamine D2 receptor in spindle cell oncocyotomas of posterior pituitary. Pituitary, 2019, 22(1):70–78. https://doi.org/10.1007/s11102-018-00935-7 PMID: 30807746
[15] Fotouhi O, Zedenius J, Höög A, Juhlin CC. Regional differences in somatostatin receptor 2 (SSTR2) immunoreactivity is coupled to level of bowel invasion in small intestinal neuroendocrine tumors. Neuro Endocrinol Lett, 2018, 39(4):305–309. PMID: 30531706
[14] Öberg K. The genesis of the neuroendocrine tumors concept: from Obendorfer to 2018. Endocrinol Metab Clin North Am, 2018, 47(3):711–731. https://doi.org/10.1016/j.ecl.2018.05.003 PMID: 30098726

[15] Lejon H, Remes S, Hagström J, Louhimo J, Mäenpää H, Schalin-Jäntti C, Miettinen M, Haglund C, Ana J. Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas. Hum Pathol, 2019, 86:66–75. https://doi.org/10.1016/j.humpath.2018.11.020 PMID: 30529752

[16] Poiană C, Neamțu MC, Avramescu ET, Carpoțe M, Tîrțănescu R, Terzea D, Neamțu OM, Dânculescu Mulescu R. The poor prognosis factors in G2 neuroendocrine tumor. Rom J Morphol Embryol, 2013, 54(3 Suppl):717–720. PMID: 24322017

[17] Poiană C, Neamțu MC, Avramescu ET, Carpoțe M, Tîrțănescu R, Terzea D, Neamțu OM, Dânculescu Mulescu R. The dedifferentiation of neuroendocrine tumor metastases: myth or reality? Rom J Morphol Embryol, 2013, 54(1):201–203. PMID: 23529331

[18] Poiană C, Carpoţe M, Ardeleanu C, Terzea D, Avramescu ET, Neamțu MC, Dânculescu Mulescu R. The value of the immunohistochemistry in a case of gastric neuroendocrine tumor and thyroid metastasis. Rom J Morphol Embryol, 2013, 52(1):187–192. PMID: 21424054

[19] Carmona Matos DM, Jang S, Hijaz B, Chang AW, Lloyd RV, Chen H, Jaskula-Sztul R. Characterization of somatostatin receptor (SSTRs) expression and antiproliferative effect of somatostatin analogues in aggressive thyroid cancers. Surgery, 2019, 165(1):64–68. https://doi.org/10.1016/j.surg.2018.05.077 PMID: 29685592

[20] Herac M, Niederle B, Raderer M, Krebs M, Kaserer K, Kopecek O. Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis. APMIS, 2016, 124(10):F250–F254. PMID: 27093746

[21] Kammerer D, Athelogou M, Lupp A, Lenhardt I, Schulz S, Luise P, Hommann M, Prasad V, Binnig G, Baum RP. Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis. Rom J Morphol Embryol, 2011, 52(1):187–192. PMID: 21424054

[22] Chabali M, Duluc C, Caron P, Vezzosi D, Guillerm-Guibert J, Pyronnert S, Bousscit C. Somatostatin analogs: does pharmacology impact antitumor efficacy? Trends Endocrinol Metab, 2014, 25(3):115–127. https://doi.org/10.1016/j.tem.2013.11.003 PMID: 24405892

[23] Sato A, Arigo M, Ardeleanu C, Terzea D, Neamțu OM, Tîrțănescu R, Năstase M, Ardeleanu C, Terzea D, Avramescu ET, Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Jiménez-Vacas JM, Vezzosi D, Caron P, Pyronnet S. Growth hormone-secreting adenomas: role of its physiological inhibitor, somatostatin: a review of the literature. Neuro Endocrinol Lett, 2018, 39(3):179–188. PMID: 30431745

[24] Sato A, Arigo M, Ardeleanu C, Terzea D, Neamțu OM, Tîrțănescu R, Năstase M, Ardeleanu C, Terzea D, Avramescu ET, Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Jiménez-Vacas JM, Vezzosi D, Caron P, Pyronnet S. Growth hormone-secreting adenomas: role of its physiological inhibitor, somatostatin: a review of the literature. Neuro Endocrinol Lett, 2018, 39(3):179–188. PMID: 30431745

[25] Lopes MBS. Growth hormone-secreting adenomas: pathology and cell biology. Neurosurg Focus, 2010, 29(4):E2. https://doi.org/10.3171/2010.7.FOCUS10169 PMID: 20887127

[26] Treppiedi D, Peverelli E, Giardino E, Ferrante E, Calebri D, Spada A, Mantovani G. Somatostatin receptor type 2 (SSTR2) internalization and intracellular trafficking in pituitary GH-secreting adenomas: role of scaffold proteins and implications for pharmacological resistance. Horm Metab Res, 2017, 49(4):259–268. https://doi.org/10.1055/s-0042-116025 PMID: 27632151

[27] Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M. Somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary, 2013, 16(4):499–508. https://doi.org/10.1007/s11128-012-0445-1 PMID: 23184260

[28] Chiloiro S, Giampietro A, Bianchi A, Tartaglione T, Bima C, Vita MG, Spinello M, Pontecorvi A, De Marinis L. Acromegaly can be cured by first-line pasireotide treatment? Endocrinol Metab Clin North Am, 2019, 64(1):196–198. https://doi.org/10.1016/j.ecl.2020.01.017 474–480. PMID: 30798431
[44] Coopmans EC, Muhammad A, van der Lely AJ, Janssen JAMJL, Neggers SJCM. How to position pasireotide LAR treatment in acromegaly. J Clin Endocrinol Metab, 2019, 104(6):1978–1988. https://doi.org/10.1210/jc.2018-01979 PMID: 30608534

[45] Orlew ska E, S tę pień R, Orlew ska K. Cost-effectiveness of somatostatin analogues in the treatment of acromegaly. Expert Rev Pharmacoecon Outcomes Res, 2019, 19(1):15–25. https://doi.org/10.1080/14737716.2018.1513330 PMID: 30122081

[46] Shimon I, Adnan Z, Gorschtein A, Baraf L, Saba Khazen N, Gershinsky M, Pa uker Y, Abid A, Niven MJ, Shechner C, Greenman Y. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study. Endocrine, 2018, 62(2):448–455. https://doi.org/10.1007/s12020-018-1690-5 PMID: 30051198

[47] Ezzat S, Caspar-Bell GM, Chik CL, Denis MC, Domingue ME, Imran SA, Johnson MD, Lochnan HA, Grégoire Nyomba BL, Prebani A, Ridout R, Ramírez JAR, Van Uum S. Predictive markers for postsurgical medical management of acromegaly: a systematic review and consensus treatment guideline. Endocr Pract, 2019, 25(4):379–393. https://doi.org/10.4158/EP-2018-0500 PMID: 30657362

[48] Gheorghisan-Galateanu AA, Carsote M, Valea A. Incidentaloma: from general practice to specific endocrine frame. J Pak Med Assoc, 2017, 67(6):917–922. PMID: 28585593

[49] Gheorghisan-Galateanu AA, Terzea D, Valea A, Carsote M. Menopausal androgen excess – associated cardio-metabolic risk: clues for ovarian Leydig cell tumor (case report and mini-review of literature). Acta Endocrinol (Bucharest), 2017, 13(3):356–363. https://doi.org/10.4183/aeb.2017.356 PMID: 31149200 PMCID: PMC6516568

[50] Carsote M, Păun S, Neamţu MC, Avramescu ET, Iosif C, Terzea D, Constantinoiu S, Dănculescu Mu lescu R, Neamţu OM, Poiană C. The immunohistochemistry aspects in two cases of neurofibromatosis-associated abdominal tumors. Rom J Morphol Embryol, 2012, 53(2):401–405. PMID: 22732814

[51] Refardt J, Holland J, Kwadwo A, Nicolas GP, Rottenburger C, Fani M, Wild D, Christ E. Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges. Rev Endocr Metab Disord, 2020 Jun 3. https://doi.org/10.1007/s11154-020-09552-x PMID: 32495250

[52] Poiana C, Carsote M, Trifanescu R, Terzea D, Croitoru A. Case study of appendiceal carcinoid during pregnancy. J Med Life, 2012, 5(3):325–328. PMID: 23049637 PMCID: PMC3465003

[53] Carsote M, Valea A. Neuroendocrine tumours: 2016 update. Acta Medica Transilvania, 2016, 21(3):41–44. http://www.amtsibiu.ro/Arhiva/2016/nr3-en/Carsote.pdf

[54] Lee DY, Kim YI. Prognostic value of maximum standardized uptake value in 111Ga-somatostatin receptor positron emission tomography for neuroendocrine tumors: a systematic review and meta-analysis. Clin Nucl Med, 2019, 44(10):777–783. https://doi.org/10.1097/RLU.0000000000002694 PMID: 31283601

[55] Ivanidze J, Roytman M, Sasson A, Skafida M, Fahey TJ 3rd, Osborne JR, Dutreul SP. Molecular imaging and therapy of somatostatin receptor positive tumors. Clin Imaging, 2019, 56:146–154. https://doi.org/10.1016/j.clinimag.2019.04.006 PMID: 31121520

Corresponding author
Mara Carsote, Lecturer, MD, PhD, Department of Endocrinology, Carol Davila University of Medicine and Pharmacy, C. I. Parhon National Institute of Endocrinology, 34–38 Aviatorilor Avenue, Sector 1, 011863 Bucharest, Romania; Phone +40744–851 934, e-mail: carsote_m@hotmail.com

Received: May 4, 2020
Accepted: December 18, 2020